目的:探讨联合检测结直肠癌(colorectal cancer,CRC)患者术前血清尿酸(uric acid,UA)与糖类抗原199 (carbohydrate antigen 199,CA199)对CRC患者TNM分期及预后的判断价值.方法:收集164例Ⅱ和Ⅲ期CRC手术患者资料,包括患者的临床、病理特征及术前血清UA、癌胚抗原(carcinoembryonic antigen,CEA)和CA199等指标.分别以UA和CA199中位数为临界值,根据检验结果将患者分为4组:UA(-)/CA199(-)、UA(+)/CA199(-)、UA(-)/CA199(+)和UA(+)/CA199(+);采用x2检验对4组患者间临床病理资料进行比较,Kaplan-Meier法分析患者的生存情况,COX风险回归模型对可能影响结直肠癌患者预后的因素进行分析.结果:4组患者间年龄、性别、吸烟状态和美国东部协作肿瘤组(Eastern Cooperative Oncology Group,ECOG)评分结果差异均无统计学意义(P值均＞ 0.05),TNM分期、组织学分级、是否有脉管和(或)神经侵犯、无病生存期(disease-free survival,DFS)和总生存期(overall survival,OS)间差异均有统计学意义(P值均＜0.05).其中UA(+)/CA199(+)组患者DFS和OS期最短,UA(-)/CA199(-)组患者DFS和OS期最长,差异有统计学意义(P值均＜0.05).单因素分析结果显示,CRC患者预后与UA.(P=0.003)、CA199 (P=0.028)、TNM (P=0.001)分期及组织学分级(P=0.001)相关;多因素回归分析显示,UA (P=0.011)、TNM分期(P=0.003)和组织学分级(P=0.002)是影响CRC患者预后的独立危险因素.结论:CRC患者术前血清UA和CA199水平与肿瘤分期及预后相关.临床上联合检测UA与CA199对CRC患者的预后评估具有一定价值.

目的 探讨小剂量奥沙利铂的FOLFOX方案治疗大肠癌患者的临床疗效.方法 回顾性分析2018年6月-2019年6月期间于河南省人民医院接受治疗的大肠癌患者(106例)的临床资料,依据药物治疗方案的不同分为对照组(常规剂量奥沙利铂的FOLFOX方案,52例)与观察组(小剂量奥沙利铂的FOLFOX方案,54例)两组.两组均连续治疗4个周期,观察两组入选者临床疗效,并对比两组入选者治疗前后生存质量,同时统计两组入选者不良反应发生情况.结果 两组客观缓解率比较,差异无统计学意义(P＞0.05);治疗后,两组入选者WHOQOL-100评分均高于治疗前,且与对照组相比,观察组较高,差异有统计学意义(P＜0.05);与对照组相比,观察组神经病变发生率较低,差异有统计学意义(P＜0.05);两组恶心、呕吐、肝功能损伤、脱发、腹泻发生率比较,差异无统计学意义(P＞0.05).结论 小剂量奥沙利铂的FOLFOX方案治疗大肠癌患者与常规剂量奥沙利铂的FOLFOX方案临床疗效无显著差异,但利于改善患者生存质量,不会增加不良反应发生风险.

目的 评价胃癌患者化疗期间加入结构脂肪乳治疗对改善患者生活质量、疗效及不良反应的影响.方法 选取2018年1月-2018年12月河南省人民医院收治的80例初治局部晚期不可手术或晚期转移性胃癌患者,随机分为试验组(40例)和对照组(40例),对照组采用胃癌一线化疗方案,试验组化疗同时加入结构脂肪乳治疗.观察两组患者主观整体评估(patient-generated subjective globe assessment,PG-SGA)、生活质量(quality of life,QOL)、体重、白蛋白、前白蛋白的变化及化疗有效率、无进展生存期和治疗相关不良反应.结果 试验组和对照组PG-SGA治疗后均较前明显下降,QOL、白蛋白、前白蛋白治疗后均较前明显上升,试验组治疗后体重较前明显上升,而对照组较前下降,差异均有统计学意义(P＜0.05).试验组治疗后PG-SGA下降数值更明显,试验组QOL、体重、白蛋白、前白蛋白升高的数值更明显,差异均有统计学意义(P＜0.05).试验组和对照组骨髓抑制及消化道不良反应发生率无统计学意义(P＜0.05),但试验组不良反应的程度较对照组明显减轻(P＜0.05).试验组的客观有效率(60.0％)和疾病控制率(85.0％)明显高于对照组(37.5％,75.0％)(P＜0.05).试验组PFS 8.0个月,对照组PFS 7.5个月,试验组PFS较对照组略有升高,但差异无统计学意义(P =0.103).结论 化疗联合结构脂肪乳可以改善患者的一般情况,并提高治疗有效率,耐受性良好.

目的:分析非小细胞肺癌骨转移患者预后的影响因素.方法:选取所在医院2015年3月至2018年10月收治的33例非小细胞肺癌患者,均发生骨转移,对其临床资料进行回顾性分析,对影响预后的因素进行分析.结果:本组33例患者骨转移位置主要集中在脊柱、胸部、骨盆上,其中脊柱转移率(48 48％)最高;单因素分析结果显示:骨转移灶位置、骨转移灶数量、病理类型、ECOG评分、ALP水平与患者总生存时间(预后)有关(P＜0 05);多因素分析结果表明,骨转移灶数量、ECOG评分、ALP水平是影响患者预后的独立危险因素(P＜0.05).结论:非小细胞肺癌患者发生骨转移后,可增加临床治疗难度,预后影响因素比较多,对影响因素进行详细分析,从而制定可行治疗方案.

目的 探讨阿帕替尼治疗常规化疗失败的晚期结直肠癌的临床效果.方法 收集本院2016年1月至2018年1月收治的经二线化疗失败的晚期结直肠癌患者60例,根据实际的治疗选择,将其中接受阿帕替尼治疗的29例患者纳入治疗组,采取姑息支持治疗的31例患者纳入对照组.比较两组患者近、远期疗效及不良反应发生情况.结果 治疗组患者客观缓解率(objective response rate,ORR)显著高于对照组(P＜0.05),中位无进展生存期显著长于对照组(P＜0.05);治疗组患者不良反应发生率显著高于对照组(P＜0.05),但以1～2级不良反应居多.结论 阿帕替尼治疗晚期结直肠癌患者的临床效果显著,可明显提高ORR,延长患者无疾病进展生存时间,且不良反应可控.

目的:探讨核转录因子神经胶质瘤关联癌基因同源物1(glioma associated oncogene homolog 1,Gli-1)对转化生长因子-β1(transforming growth factor-β1,TGF-β1)诱导的人胃癌SGC-7901细胞发生上皮间质转化(epithelial-mesenchymal transition,EMT)的作用机制.方法:体外采用10 ng/ml TGF-β1对胃癌SGC-7901细胞进行处理,使用倒置显微镜观察细胞形态变化,RT-PCR和Western blot检测EMT上皮表型蛋白E-cadherin和间质表型蛋白Vimentin的表达水平;Transwell细胞侵袭实验检测细胞侵袭能力变化,检测TGF-β1对SGC-7901细胞发生EMT的影响;同时采用RT-PCR和Western blot检测Gli-1的mRNA和蛋白表达水平.随后进一步采用Gli-1基因特异性阻断剂GANT 61阻断Gli-1表达,并使用TGF-β1(10 ng/ml)对SGC-7901细胞进行处理,RT-PCR和Western blot检测Gli-1、E-cadherin和Vimentin mRNA及其蛋白表达水平的改变,并使用Transwell细胞侵袭实验检测阻断Gli-1对SGC-7901细胞侵袭能力的影响.结果:TGF-β1可以诱导人胃癌SGC-7901细胞发生上皮间质转化并促进细胞侵袭.TGF-β1可以在mR-NA和蛋白水平下调上皮表型蛋白E-cadherin的表达、提高Gli-1和间质表型蛋白Vimentin的表达.TGF-β1可以明显提高SGC-7901细胞侵袭,而阻断Gli-1后可以抑制TGF-β1诱导的人胃癌SGC-7901细胞上皮间质转化和细胞侵袭.结论:胃癌SGC-7901细胞中Gli-1可能参与TGF-β1介导的EMT的发生,Gli-1可能作为胃癌基因治疗中的有效靶点发挥作用.

Objective To evaluate the effect of early interventionon the prognosis of patients with severe tumor in the general wards during hospitalization and eventually transferred to ICU.Methods The medical emergency team (MET) was established in the oncology department of our hospital.MET startup standards were draught up.Early intervention for patients with severe tumor with physiological disturbances and eventually admitted to ICU.The patients were divided into survival group and death group according to whether the patient died in hospital;and divided into pre-intervention group and post-intervention group according to different timing of patient intervention.The effect of early intervention and early intervention time on the prognosis of each group was compared.Cox proportional hazards model was used to evaluate the independent factors affecting the prognosis of patients.Results A total of 449 patients with severe tumor were treated with MET and transferred from general ward to ICU.145 (32.3％) patients died during their stay in ICU.The intervention time (t =21.095,P ＜0.001) of the death group was significantly higher than that of the survival group[(2.98 ±0.82) h vs.(1.32 ± 0.47) h,t =21.095,P ＜ 0.001].The ICU mortality [18.0％ (34/189) vs.42.3％ (110/260),x2 =29.709,P ＜ 0.001],hospital mortality [39.7％ (75/189) vs.67.7％ (176/260),x2 =34.831,P ＜ 0.001],30-day mortality[29.1％ (55/189) vs.55.0％ (143/260),x2 =29.780,P ＜0.001],and 1 year cumulative mortality (log-rank test,P =0.029) in the pre-intervention group were significantly lower than those in the post-intervention group.Cox proportional hazard model analysis showed that the intervention time (HR =1.027,95％ CI 1.017 ～ 1.037,P ＜ 0.001) was positively correlated with the 1 year mortality rate.Early intervention (HR =0.456,95％ CI 0.348 ～0.597,P ＜ 0.001) and early intervention in earlier stage(HR =0.485,95％ CI 0.372 ～ 0.633,P ＜0.001) were negatively correlated with 1 year mortality rate.Conclusion Early intervention can significantly improve the short-term and long-term prognosis of patients with severe tumor in the general ward.Therefore,early identification and timely treatment are of great significance.

目的 探讨替莫唑胺联合放射治疗脑转移瘤的临床效果.方法 选取脑转移瘤患者92例,按照就诊先后顺序分为研究组(替莫唑胺+放射)与对照组(单纯放射).随访24个月,对比2组临床疗效、复发时间、生存时间、生存质量、不良反应等.结果 2组临床缓解率比较差异有统计学意义(P<0.05);随访24个月,研究组复发时间、生存时间均长于对照组,差异有统计学意义(P<0.05);治疗前,2组生存质量评分对比差异无统计学意义(P>0.05);治疗后,2组生存质量评分较治疗前有所改善,且研究组优于对照组,差异有统计学意义(P<0.05);2组不良反应发生率差异有统计学意义(P<0.05).结论 脑转移瘤采用替莫唑胺联合放射治疗的效果更为理想,能延长患者生存时间,提升生存质量,且能减少不良反应,安全可靠.

Objective To investigate the mechanism of lutein on the proliferation and apoptosis of human prostate cancer PC3 cells, and to provide a new theoretical basis for the treatment and prevention of prostate cancer. Methods CCK8 assay was used to detect the proliferation of PC3 cells treated with different concentrations of lutein; flow cytometry was used to detect the changes of cell cycle distribution and apoptosis after 48 h; cell scratch (wound healing) and Transwell experiment was applied to observe cell migration and invasion; the mRNA and protein expression levels of Bcl-2 and Bax were detected by RT-PCR and Western blot. Results Lutein significantly inhibited the proliferation of PC3 cells in a time- and dose-dependent manner. Lutein could block the growth of PC3 cells in G0/G1 phase and inhibit cell migration and invasion; it could induce cell apoptosis, downregulate the expression of Bcl-2 and upregulate the expression of Bax. RT-PCR results showed that lutein could downregulate Bcl-2 mRNA expression and upregulate Bax mRNA expression in a dose-dependent manner. Conclusion Lutein could inhibit the proliferation and promote the apoptosis of human prostate cancer PC3 cells. The mechanism may be related to blocking cell cycle, inhibiting cell migration and invasion, as well as regulating apoptosis-related gene and protein expression.

Objective To investigate the primary chemoresistance-related microRNA(miRNA) in refractory epithelial ovarian cancer, to lay a foundation for further study of miRNA related biological pathways. Method Clinical profile and tissue samples of 100 cases of epithelial ovarian cancer in FIGO stage IIb to IIIc treated with optimal cytoreductive sur-gery and paclitaxel plus carboplatin chemotherapy were collected. Based on postoperative chemotherapy responses, the patients were stratified as chemosensitive group and chemoresistant group. 3 patients in each group were selected and ana-lyzed using TaqMan Real-time PCR miRNA Array analysis to identify significantly expressed miRNA. Based on the pre-diction of target gene and analysis of miRNA and its target genes in tumor, the target miRNA was screened as distin-guished biomarkers for differentiating patients with high platinum-sensitivity and refractory disease. Result TaqMan Re-al-time PCR miRNA Array identified 118 significantly expressed miRNA. 76 miRNA were highly expressed and 42 were with lower expression in patients with refractory disease compared to those with high platinum-sensitivity. According to the existing literature and target gene prediction analysis, 6 miRNA were screened as the target miRNA to differentiate pa-tients with refractory disease or with high platinum-sensitivity. Compared with high sensitivity group, the expression of miR-21 and miR-27a were significantly increased (P<0.001) and the expression of miR-100, miR-770-5p, miR-200c and miR-497 were significantly lower (P<0.05) in the refractory disease group. Conclusion The 118 miRNA screened by TaqMan Real-time PCR miRNA Array may be associated with drug resistance in epithelial ovarian cancer. The high ex-pression of miRNA-21 and miRNA-27a, low expression of miRNA-100, miRNA-770-5p, miRNA-200c, and miRNA-497 may indicate the primary chemoresistance in epithelial ovarian cancer.

Objective To observe the therapeutic effect of paclitaxel and TACE (transcatheter arterial chemoembolization) combined with chemotherapy in the treatment of liver metastasis from colorectal cancer. Methods 62 cases of colorectal cancer patients with liver metastasis in our hospital were selected, the random number table method was divided into observation group and control group, each of 31 cases. The control group was treated with docetaxel based chemotherapy, the observation group was treated with paclitaxel and TACE regimen combined with chemotherapy, after 3 cycles of treatment, the remission rate of the twogroups were compared.ResultsThe remission rate of observation group was 70.97%, higher than that of control group 38.71%, and the difference was statistically signiifcant (P<0.05).Conclusion Paclitaxel combined with TACE chemotherapy in the treatment of liver metastasis from colorectal cancer can effectively improve the rate of lesion.

目的:研究叶黄素对于核因子相关因子2(nuclear factor erythroid-2 related factor 2,Nrf-2)和血红素加氧酶-1(heme oxygenase-1,HO-1)表达的影响,从而研究叶黄素对人结肠癌HT29细胞增殖的抑制作用及其可能的机制.方法:用不同浓度的叶黄素(20、40、80、120、160 mg/L)和空白对照组(0 mg/L)处理HT29细胞24、48、72 h,用CCK8法检测叶黄素对该细胞增殖的抑制作用.流式细胞仪检测细胞周期.RT-PCR检测Nrf-2和HO-1RNA表达水平的变化.Western blot检测Nrf-2和HO-1的蛋白表达水平的变化.结果:叶黄素能够抑制人结肠癌HT29细胞的增殖,160 mg/L叶黄素作用72 h后,抑制率可高达78.09％,且具有剂量依赖性和时间依赖性.流式细胞仪检测细胞周期结果显示:叶黄素作用于HT29细胞48 h后,G0/G1期细胞显著增加.表明叶黄素可阻滞HT29细胞生长于G0/G1期.RT-PCR检测和Westernblot检测的结果共同显示,经过不同浓度的叶黄素处理后,Nrf-2和HO-1 RNA的表达水平以及蛋白的表达水平与未经叶黄素处理的对照组相比明显上调,且具有剂量依赖性(P ＜0.O1).结论:叶黄素可显著抑制HT29细胞的增殖,使其细胞周期阻滞在G0/G1期.同时诱导Nrf-2和HO-1 RNA和蛋白的表达,这可能是其抑制HT29细胞增殖、发挥保护作用的重要机制.

Objective To evaluate the use of DC-CIK combined with chemotherapy plus targeted therapy for advanced colorectal cancer clinical therapeutic value.Methods Randomly selected 60 patients with advanced colon cancer from July 2012 to December 2014 in our hospital, according to the different treatment methods were divided into the control group and the observation group, the observation group adopt line combination chemotherapy plus DC-CIK targeted therapy, the control group underwent chemotherapy plus targeted therapy for clinical treatment, of two groups of patients were analyzed retrospectively.Results The tumor control rate was&nbsp;observed in patients, the incidence of side effects was better than the control group,P<0.05, had difference statistically significance.ConclusionDC-CIK combined with chemotherapy plus targeted therapy for patients with advanced colorectal cancer treatment, can effectively enhance the treatment options for tumor cell destruction, it is a reliable method of treatment.

Objective To investigate the expression of steroid receptor coactivator-3(SRC-3)in the hepatocellu-lar carcinoma tissues and its relationship with clinicopathological features. Methods immunohistochemical staining and RT-PCR were used to detect SRC-3 protein and mRNA expression levels in the 80 cases of hepatocellular carci-noma and paraneoplastic tissues. Results The positive expression rate of SRC-3 protein in hepatocellular carcinoma tissues was 56. 25% ,which was significantly higher than that(8. 75% )in the paraneoplastic tissues(P ﹤ 0. 05). SRC-3 mRNA was high level transcription in the 58 cases of hepatocellular carcinoma,and was 12 cases in the para-neoplastic tissues,SRC-3 mRNA transcription level in the hepatocellular carcinoma was significantly increased than the paraneoplastic tissue(P ﹤ 0. 05). The positive rate of SRC-3 protein expression in the patients with hepatitis B virus(HBV)infection was 63. 49% ,which was significantly higher than that(29. 41% )of patients with non HBV infection,the difference was statistically significant(P ﹤ 0. 05);the positive rate of SRC-3 protein expression in the patients with alpha-fetoprotein(AFP) ﹤ 400 ng·mL - 1 was 76. 19% ,significantly higher than that(49. 15% )in the patients with AFP≥400 ng·mL - 1 ,the difference was statistically significant(P ﹤ 0. 05);the positive rate of SRC-3 protein expression in the patients with high differentiated hepatocellular carcinoma was 88. 24% ,significantly higher than that(47. 62% )in the patients with inmiddle and low differentiated hepatocellular carcinoma,the differ-ence was statistically significant(P ﹤ 0. 05). Conclusion SRC-3 high expression is related with the canceration and progression of hepatocellular carcinoma,and may become a potential molecular marker or therapeutic target.

目的:研究叶黄素对结肠癌HT29细胞的增殖抑制作用及可能的机制.方法:用不同浓度的叶黄素(20、40、80、160 mg/L)和空白对照组(0 mg/L)干预处理培养的HT29细胞24、48、72 h,采用SRB法检测其对该细胞的增殖抑制作用;流式细胞仪检测细胞周期;Hoechst33342/PI荧光染色法检测细胞凋亡;Western blot检测磷酸化ERK(phosphorylation of ERK,p-ERK)、磷酸化p38(phosphorylation of p38,p-p38)蛋白表达水平的变化.结果:叶黄素能抑制HT29细胞增殖,且有明显的剂量和时间依赖性.流式细胞仪检测细胞周期结果显示,叶黄素(80 mg/L)干预处理HT29细胞48 h后,G0/G1期细胞由58.67％增加至63.23％,且随药物浓度增加,G0/G1期细胞显著增加,当叶黄素浓度为160mg/L时,G0/G1期细胞增加至70.81％,表明叶黄素可将HT29细胞阻滞在G0/G1期;Hoechst33342/PI荧光染色法检测细胞凋亡结果显示,叶黄素可诱导HT29细胞凋亡;Western blot检测结果显示叶黄素可下调p-ERK、上调p-p38蛋白的表达,有浓度依赖性(P＜0.01).结论:叶黄素可显著抑制HT29细胞的增殖并诱导其凋亡,使细胞周期阻滞在G0/G1期;下调p-ERK蛋白、上调p-p38蛋白的表达可能是其诱导细胞凋亡的重要机制.

Aim:To research risk factors of malignant tumors with deep venous thrombosis(DVT),and the influence of DVT on the prognosis of patients with malignant tumors.Methods:A total of 54 cases of malignant tumor with DVT(the case group) and 54 cases of malignant tumors at the same period but not companying with DVT(the control group) were collected.The survival difference between the two groups was compared by Kaplan-Meier test and at the same time the risk factors of malignant tumors with DVT were analyzed.Results:The median survival time of the case and the control groups were respectively 15 months and 17 months,and there was significant difference(χ2=6.822,P=0.009).Surgery and trauma were the risk factors [OR=3.375 and 4.534,95%CI=(1.417～8.040) and(1.118～14.675)].Conclusion:DVT is one of the poor prognosis indexes for malignant tumor.Surgery and trauma are risk factors of malignant tumors with DVT.

OBJECTIVE: To study the improvement effect of Bifidobacterium on intestinal permeability in stress model rats,and synergistic reaction of Bifidobacterium combined with Montmorillonite powders.METHODS: 50 SD rats were randomly divided into normal control group,model control group,Bifidobacterium treatment group(2×108 cfu),Montmorillonite powders treatment group(0.6 g·kg-1) and drug combination group(Bifidobacterium 2×108 cfu+Montmorillonite powders 0.6 g·kg-1).Those rats were given medicine once a day via i.g.for consecutive 7 days.Stress model was established by WAS in the latter 4 groups.On 8th day each group was given mannitol 80 mg and sucralose 60 mg,and the amount and ratio of mannitol and sucralose in urine were determined 5 h and 24 h after administration to evaluate intestinal permeability.Rats were sacrificed at the end of experiment,and the content of corticotrophin releasing factor(CRF) and adrenocorticotrophic hormone(ACTH) in serum were determined.RESULTS: Compared with normal control group,the 24 h mannitol concentration,the serum levels of CRF and ACTH in model control group increased significantly(P0.05).Compared with model control group,serum levels of ACTH in Bifidobacterium treatment group and drug combination group decreased significantly(P0.05).Other parameters all decreased but had no statistical significance.CONCLUSION: Bifidobacterium can improve intestinal permeability of stress model rats,protect intestinal mucosa.In the treatment of intestinal dysfunction caused by chronic psychological stress,Bifidobacterium and Montmorillonite powders are not in synergies.

<正>0引言原发性心脏血管肉瘤是一类临床罕见的、恶性程度高的心脏恶性肿瘤。由于其发病率低,临床认识不足,往往难以早期诊断。我院于2009年收治1例,现报道如下。1临床资料患者,男,29岁,因咳嗽伴右侧胸痛,活动后心慌、气短、胸闷25天,于2009年9月14日入院。外院行心脏彩超示:(1)左右房多发中等回声团(血栓还是实性肿块?);(2)双房大;(3)二、三尖瓣少量反流。口服通心络

目的 探讨叶黄素对胃癌SGC - 7901细胞的增殖抑制效应及其凋亡机制.方法 通过SRB法、Hoechst33342/PI荧光染色法观察叶黄素对胃癌SGC-7901细胞的生长抑制作用及诱导凋亡机制,并采用荧光分析法检测叶黄素作用SGC-7901细胞后细胞内ROS的变化.结果 40mg/L的叶黄素作用SGC - 7901细胞24,48,72 h的抑制率分别是(8.57±2.43)％、(25.07±2.90)％和(32.33±1.81)％；160mg/L的叶黄素作用SGC - 7901细胞的抑制率上升为(34.72±4.06)％、(64.55±2 48)％和(83.29±0.10)％.Hoechst33342/Pl荧光染色法检测细胞的凋亡情况,对照组显示低蓝光低红光,40mg/L部分显示高蓝光低红光,80 mg/L大部分显示高蓝光低红光,160 mg/L的大部分显示低蓝光高红光；荧光分光光度计检测叶黄素作用胃癌SGC -7901细胞后细胞内ROS的活性变化,结果显示随着叶黄素浓度的升高,细胞内ROS的活性降低(P＜0.01).结论 叶黄素对胃癌SGC - 7901细胞的生长抑制以及诱导其凋亡的分子机制,可能是通过降低细胞内ROS的活性所介导的.

Objective:To evaluate the efficacy and toxicity of recombinant human endostatin (rh-endostatin) combined with platinum-based chemotherapy in advanced non-small cell lung cancer. Methods:One hundred and eight patients with advanced non-small cell lung cancer were randomly divided into study group (n = 54;receiving rh-endostatin combined with platinum-based chemotherapy) and control group (n = 54; receiving platinum-based chemotherapy). The short-term response rate (RR), clinical benefit rate (CBR), time to progression (TTP) and overall survival (OS) were calculated, and the changes of Karnofsky performance status (KPS) score and serum carcinoembryonic antigen (CEA) level were observed. Results:The short-term RRs of the study group and the control group were 38.46% and 18.87%, respectively (P = 0.026); the CBRs of the study group and the control group were 80.77% and 62.26%, respectively (P = 0.036). The difference in KPS score before and after treatment had no statistical significance (P0.05). The serum CEA level was significantly lower after treatment than before treatment in both groups (P0.05). The TTP was 6.2 months in the study group, while which was 4.7 months in the control group; there was a significant difference between the two groups (P = 0.022). The OS in the study group and control group were 16.2 and 14.1 months, respectively (P = 0.485). The adverse reactions between the two groups were similar, and the major adverse reactions were bone marrow suppression and gastrointestinal reactions. The rate of cardiotoxicity was higher in the study group than in the control group, but there was no difference between the two groups (P = 0.086). Conclusion: The combination of rh-endostatin and platinum-based chemotherapy can lead to a better short-term RR and a superior TTP, and it is also well tolerated.